on behalf of the PEACE Investigators Background-Heart failure (HF) is a disease commonly associated with coronary artery disease. Most risk models for HF development have focused on patients with acute myocardial infarction. The Prevention of Events with Angiotensin-Converting Enzyme Inhibition population enabled the development of a risk model to predict HF in patients with stable coronary artery disease and preserved ejection fraction. Methods and Results-In the 8290, Prevention of Events with Angiotensin-Converting Enzyme Inhibition patients without preexisting HF, new-onset HF hospitalizations, and fatal HF were assessed over a median follow-up of 4.8 years. Covariates were evaluated and maintained in the Cox regression multivariable model using backward selection if PϽ0.05. A risk score was developed and converted to an integer-based scoring system. Among the Prevention of Events with Angiotensin-Converting Enzyme Inhibition population (age, 64Ϯ8; female, 18%; prior myocardial infarction, 55%), there were 268 cases of fatal and nonfatal HF. Twelve characteristics were associated with increased risk of HF along with several baseline medications, including older age, history of hypertension, and diabetes. Randomization to trandolapril independently reduced the risk of HF. There was no interaction between trandolapril treatment and other risk factors for HF. The risk score (range, 0 to 21) demonstrated excellent discriminatory power (c-statistic 0.80). Risk of HF ranged from 1.75% in patients with a risk score of 0% to 33% in patients with risk score Ն16. Conclusion-Among patients with stable coronary artery disease and preserved ejection fraction, traditional and newer factors were independently associated with increased risk of HF. Trandolopril decreased the risk of HF in these patients with preserved ejection fraction. (Circ Heart Fail. 2009;2:209-216.)
MI in the acute and subacute phase. 12, 13 A few investigators have characterized risk factors for HF in patients with higher risk, stable CAD. 14 Moreover, angiotensin-converting enzyme (ACE) inhibitors have been demonstrated to reduce mortality and morbidity in patients with HF, MI complicated by HF, and high-risk CAD. 8, [15] [16] [17] Less is known about predictors associated with HF in lower risk patients with CAD. A better understanding of the factors involved in the eventual development of HF among these lower risk patients may enable new strategies to prevent progression of disease, preserve quality of life, and improve overall survival. The Prevention of Events with an ACE Inhibitor (PEACE) cohort of patients was a low-risk population with CAD that was the focus of this study. The aims were (a) to identify predictors of HF in a low-risk population with CAD, (b) to determine the independent impact of trandolapril on subsequent HF events, and (c) to develop a risk score to predict HF.
Methods
The design and results of the PEACE trial have been previously published. 18 Briefly, 8290 patients Ն50 years with documented CAD and documented LVEFՆ40% were randomized to trandolapril or placebo and followed for a median of 4.8 years. The primary end point was CV death, nonfatal MI, or coronary revascularization. Patients with a serum creatinine Ͼ2.0 mg/dL or who had hospitalization for unstable angina within 2 months or revascularization within 3 months were excluded. In addition, patients with a condition that required the use of an ACE inhibitor, including HF, were excluded.
Baseline characteristics were obtained by site investigators and staff and included medical history, prior MI and/or coronary revascularization, vital signs, and LVEF. Serum creatinine was obtained at baseline. Glomerular filtration rate was estimated using the 4-component Modification of Diet in Renal Disease equation, which includes serum creatinine, sex, age, and race. 19 New HF was determined by the investigators and required hospitalization for the treatment of HF or was adjudicated as the primary cause of death by a clinical end points committee. In addition, all deaths were subclassified and those deaths attributed to HF were noted. The primary outcome for this study focused on HF hospitalization or fatal HF.
Statistical Analysis
We computed descriptive statistics for all potential covariates. For each continuous variable, we tested for linearity in the log hazard using cubic splines. 20 We then used the collinearity index to check for intercorrelations among the variables. All covariates were entered into a Cox proportional hazard model, and the final model was chosen using a backward selection procedure. Of note, a forward selection procedure resulted in the same independent predictors of HF events. All 2-way interactions with treatment were tested and a probability value of 0.01 was considered significant. We tested model fit using residual analysis and the proportional hazards assumptions using the log-log survival function. 21 To validate the final Cox model, we used the methods of Assman et al. 22 We randomly divided the sample into 5 equal parts and generated models using every possible combination of 4 of the 5 sets. A c-score was computed to assess the model's predictive ability. 23 Hazard ratios (HRs) with 95% CIs are reported for the final model.
To develop a risk stratification algorithm, we assigned a point score to baseline characteristics that independently predicted congestive heart failure. A risk score was developed using the methods of Rassi et al. 24 Each coefficient was divided by the smallest coefficient and rounded to the nearest integer. Kaplan-Meier survival curves were generated for each risk score. The scores were grouped into 3 categories of risk: low (Ͻ9 points), medium (9 to 14 points), and high (Ն15 points). We used the log-rank test to test for differences in survival between the groups.
Several supportive analyses were conducted. The variables that were determined to be predictive of HF in a stable MI cohort in Cholesterol and Recurrent Events (CARE) were compared with PEACE population using a Cox proportional hazards model. Patients in the PEACE trial who experienceed a MI postrandomization were evaluated to determine the proportion of patients who had a MI before HF event. The SAS analysis system version 9.1 was used for all analyses (SAS Institute, Inc, Cary, NC).
Results
The baseline characteristics of the PEACE population have been previously reported. 18 Briefly, the mean age was 64Ϯ8 with 18% women and 31.0% having a body mass index Ͼ30 kg/m 2 . The mean LVEF was 58%Ϯ9% with only 14.9% of patients having a LVEF between 40% and 50%, the lowest eligible range of left ventricular function. The mean estimated glomerular filtration rate (eGFR) was 78Ϯ19 mL/kg/min/ 1.73 m 2 , and 16.4% of patients had stage 3 chronic kidney disease based on an eGFRϽ60 mL/kg/min/1.73 m 2 . A history of hypertension was present in 45% of patients and 55% had a prior MI. A total of 412 patients (5%) had missing quantitative values of LVEF, but systolic function was reported by echocardiography as being qualitatively preserved, and 405 patients (5%) were missing cholesterol values. The remainder of the data required for the multivariable model was available in 99% of patients. Mean arterial pressure and serum creatinine were not in the multivariable model, because they were highly correlated with systolic/diastolic blood pressure and eGFR, respectively.
Fatal and Nonfatal HF Events
During a median follow-up of 4.8 years, there were 268 patients (3.3%) of 8211 PEACE patients who had a HF event which averages to 0.7%/y. Most patients with a HF event (nϭ239) were hospitalized and 29 patients (0.35%) died of HF without ever being hospitalized. After adjudication by a blinded end points committee, patients who were felt to have died predominantly as a result of pump failure were classified as "fatal HF." Of these 268 patients, 47 (17.5%) had an acute MI between randomization and the HF event, but the majority developed HF without an interim MI. Baseline characteristics of patients are listed in Table 1 .
Multivariable analyses identified increasing age, diabetes, prior revascularization, hypertension, and current smoking as the most robust predictors of HF (Table 2) . Patients with a prior MI had a 43% increased risk of HF and patients with lower LVEF (LVEF 41% to 50%) had a 41% increased risk. Higher body mass index and lower eGFR were also associated with increased risk. Several baseline medications that were used at the discretion of the treating physician were also associated with HF development, including use of diuretic, digitalis, calcium channel blocker, or antiarrhythmic drugs. The use of lipid-lowering medicines was associated with a lower risk of HF.
Randomization to trandolapril significantly reduced the risk of HF compared with placebo after adjusting for all other predictors of HF (HR, 0.73; 95% CI, 0.57 to 0.93; Pϭ0.01). There were no significant interactions between trandolapril and each variable in the final model. The same variables were identified using forward and backward selections. Crossvalidation resulted in several variables that changed significance levels in one or more validity data sets. This included the presence of angina, LVEF stratification (40% to 50% versus Ն50%), nonrandomized use of calcium channel blockers, and history of MI. A multivariable model developed with an end point of "HF or all-cause mortality resulted in similar predictors."
Risk Score
For the purpose of risk score development, continuous variables were categorized (ie, eGFR, age, and body mass index). There was no difference in the Cox regression model when using these 3 variables as either categorized or continuous (Table 3) . Patients with eGFR Ͻ60 were at higher risk of HF (HR, 1.67; 95% CI, 1.3 to 2.2; PϽ0.001) as well as those with a body mass index Ն35 (HR, 2.09; 95% CI, 1.5 to 3.0). As expected, risk increased linearly with age. The risk score assigned to each variable ranged from 1 to 4 based on the estimate size ( Table 3 ). The risk score, calculated by the sum of scores for each patient, ranged from 0 to 21, and almost half of the patients in PEACE had a score ranging from 4 through 7. The low risk of HF events in PEACE is reflected in the distribution of events stratified by the risk score ( Figure 1 ). Patients were stratified into 3 groups based on the risk score (low risk Ͻ9, intermediate risk 9 to 14, and high risk Ͼ14). Figure 2 illustrates the HF event rates in the 3 different groups with a 5-year event rate of 2% in the group with the lowest risk, 7% risk in the group with the intermediate risk and Ͼ26% in the highest risk group. The c-statistic of the final model with the best fit was 0.79 suggesting excellent discriminatory ability. The full model with all variable entered was not significantly different with a c-statistic of 0.80.
The model used to predict HF in CARE, a population of stable, survivors of MI, a mean of 10 months beyond their acute MI without antecedent HF, was evaluated in PEACE. This model in CARE was derived from the 4 strongest predictors of HF in this population based on the multivariable model. 14 
Discussion
In a low-risk, stable CAD population with documented preserved LVEF who are well treated with contemporary therapy, most will not develop HF over a 5-year period. Among this relatively low-risk population, several risk fac- All potential variables with significance Ͻ0.05 were eligible for the final model. All variables were tested in separate Cox regression models with treatment. A backward selection procedure was used to eliminate variables at the 0.05 level of significance. The same variables remained when approached with a forward selection model. The proportional hazards assumption was tested and confirmed for all final covariates.
tors emerged among those who developed HF, including older age, diabetes, prior revascularization, and stroke. A few factors did not remain statistically significant during crossvalidation procedures and should be interpreted cautiously. LVEF did not remain in the model likely given the prerequisite normal or near normal LVEF to be randomized in PEACE. The use of lipid-lowering agents was associated with a lower likelihood of HF events. Despite this finding, most patients did not suffer from a clinically apparent MI before the HF event although microvascular ischemia or injury could not be excluded. Randomization to an ACE inhibitor significantly reduced the risk of HF development even among this low-risk group in which relatively few patients had a HF event. The lack of effect of ACE inhibitor on mortality is likely related to the relatively small proportion of patients who developed HF. Finally, nonrandomized medication use is likely a reflection of disease burden, which may contribute to their predictive ability. Analysis without these medicines did not significantly change the model.
Prevention of HF is an important goal of therapy for patients with a variety of conditions such as hypertension, diabetes, and survivors of MI and these patients have been well characterized in multiple prediction models. 14, 25, 26 Most prediction models in patients with CAD have focused on those patients with higher risk features such as low ejection fraction or vascular complications. In Heart Outcomes Prevention Evaluation (HOPE), in addition to HF hospitalization and fatal HF, the authors included HF requiring open-label ACE inhibitor and symptoms and signs consistent with HF as a part of the HF end point. 27 This higher risk population had an event rate of 10.2% over 4.5 years using the definition that included less severe HF not requiring hospitalization and/or requiring open-label ACE inhibitor. PEACE analysis confirmed several predictors of HF that were identified in the HOPE population, including older age, higher body mass index, prior CABG, diabetes, stroke, and lack of lipidlowering therapy. Approximately 80% of the HOPE patients had CAD and few patients were treated with ␤-blockers, lipid-lowering agents, and antiplatelet therapy. 28 In addition, impaired renal function was also associated with increased risk of HF in PEACE. Lower glomerular filtration rate has previously been shown to be predictive of adverse events in patients with MI 29 and chronic HF 30, 31 and has identified patients who may be more likely to benefit from medical interventions. 32 Among women with CAD, only a glomerular filtration rate Ͻ40 cc/min/m 2 was predictive of subsequent HF. 33 This increasingly recognized risk factor may be associated with HF development due to left ventricular remodeling and worsening anemia. Additional predictors identified in PEACE include presence of angina, current smoking, and history of MI.
Risk scores have been commonly developed in the prediction of a variety of outcomes in patients with CV disease. The clinical utility has been relatively low for a variety of factors, including the cumbersome use in medical decision making. This risk score uses an integer-based scoring system, which could facilitate its clinical applicability. Although it has excellent discriminatory characteristics, the very low event Angina was measured using the Canadian Classification System. Risk score calculated by using dividing each coefficient by the smallest coefficient and rounding to the nearest integer. LVEF indicates left ventricular ejection fraction, eGFR-estimated glomerular filtration rate using Modification of Diet in Renal Disease equation; HR, hazard ratio. rate in this low-risk population attenuates the overall impact of the score. Patients with intermediate and high-risk scores are at much greater risk of HF development. However, most patients had a score Ͻ9 and were at low risk. Improving the ability to stratify these lowest risk patients may impact a larger population with CAD. The addition of biomarkers may increase the precision of prediction models using clinical characteristics. Brain natriuretic peptide (BNP) and pro-BNP have been predictive of HF events in PEACE and increased the c-statistic from 0.82 using several baseline characteristics and CRP to 0.84 with BNP added and 0.85 with pro-BNP added to the model. 34 In the Heart and Soul study, pro-BNP was an independent predictor of new-onset HF in patients with stable CAD, but the number of clinical characteristics adjusted in the multivariable model was limited by the small number of events. 33 Other possible biomarkers include anemia, C-reactive protein, and cystatin C. 35 Most of the publications regarding predictors of HF in low-risk populations Figure 1 . Distribution of risk score. The score ranges from 0 to 21 with higher score representing a higher risk for hear failure development. Gray represents patients who did not develop heart failure, and white represents the patients who had an event. with CAD have focused on biomarkers or in patients with imaging evidence of ischemia. 36 The use of ACE inhibitors has been established as clearly beneficial in a variety of patient populations, including those with chronic HF across the spectrum of disease severity, patients with MI, low LVEF, and/or signs of HF, diabetes mellitus with proteinuria, and complicated patients with CAD and high-risk features. The current guidelines recommend ACE inhibitors as a class IIa indication for patients with CAD and normal to mildly reduced LVEF. 37 In HOPE and the European trial on reduction of cardiac events with perindopril in stable coronary artery disease (EUROPA), ACE inhibition decreased CV risk and mortality. 17, 38 In a lower risk population in PEACE with documented preserved LVEF, randomization to trandolapril reduced HF development, but not the primary end point or mortality. This efficacy was seen after adjusting for factors associated with HF development. Based on other studies, HF development was associated with a 4-to 9-fold increased mortality, and prevention of this complication of CAD may attenuate this mortality. 14, 27 Longer follow-up in patients at less risk of mortality may enable realization of benefit of ACE inhibition. Also, HF management costs an estimated 29 billion dollars annually in the United States alone and prevention of HF development in patients with CAD would decrease the economic burden of CV disease. Patients who develop HF have a distinctly different life trajectory with decreased survival, increased anxiety and depression, and worse quality of life. Finally, a meta-analysis of HOPE, EUROPA, and PEACE demonstrated consistent reduction in CV events and HF. 39 There are several limitations to this study. First, several predictors in the final model were nonrandomized medications, and we cannot adjust for the underlying rationale for their use by the treating physician. However, this may improve the significance of the other variables as it may further adjust for disease severity. We did not include the milder forms of HF, such as those patients who did not require HF hospitalization. This group has worse subsequent mortality, albeit not as high as those requiring hospitaliza-tion. 40 In HOPE, these patients who required open label ACE inhibitor or had symptoms consistent with HF were included in the final model, and our study confirms the value of ACE inhibition even when focused on the more severe HF events. Also, there were a small percentage of patients who developed HF in this very low-risk population. The absolute number of patients with HF events, however, enabled the development of a robust multivariable model. We do not have LVEF assessment at the time of the HF event and cannot subclassify into low versus preserved LVEF. However, the quality of life and symptom burden of these patients are similar irrespective of LVEF. 41 Despite these limitations, this study expands our understanding of predictors of HF among a low-risk population with CAD and demonstrated the independent effect of ACE inhibition in reducing this risk.
Conclusions
This analysis demonstrates that several traditional and easily available factors are associated with a greater risk of HF development, even among a low-risk population with CAD. ACE inhibition reduces the risk of HF among this low-risk population irrespective of these factors. As the prevalence of CAD continues to increase, more aggressive secondary prevention efforts and newer therapies can target those patients among this low-risk group who may derive the greatest benefit from more aggressive interventions and the risk score may be used to stratify patients for future clinical trials. *Low risk was defined as a patient younger than 55 years with LVEF Ͼ50% and did not have diabetes or hypertension. High risk was defined as patients older than 60 years with LVEF Յ50% and both diabetes and hypertension. All other patients were intermediate risk.
†Low risk was defined as a PEACE HF risk score Ͻ9, intermediate patients had a risk score of 9 -14 and high-risk patients had a risk score Ͼ14.
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